I-Oxin Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 11 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 1.00 M
- Revenue Growth -51.51%
- Profit Growth -28.54%
- Ebitda 30.20%
- Net Worth 5.38%
- Total Assets -5.74%
About I-Oxin Pharma
I-Oxin Pharma Private Limited (IPPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 March 2015 (Nine years and 11 months 16 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Praveen Tripathi and Poonam Devi serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74120MH2015PTC262595
- Company No.
262595
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Mar 2015
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does I-Oxin Pharma Private Limited offer?
I-Oxin Pharma Private Limited offers a wide range of products and services, including Hair Growth Medicine, Hair Loss Medicines, Dietary Supplements, Omega 3 Capsule.
Who are the key members and board of directors at I-Oxin Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Praveen Tripathi  | Director | 10-Mar-2015 | Current |
| Poonam Devi | Director | 14-Mar-2022 | Current |
Financial Performance of I-Oxin Pharma.
I-Oxin Pharma Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 51.51% decrease. The company also saw a substantial fall in profitability, with a 28.54% decrease in profit. The company's net worth moved up by a moderate rise of 5.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of I-Oxin Pharma?
In 2021, I-Oxin Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pvmt Pharma Private LimitedPraveen Tripathi and Poonam Devi are mutual person
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Jan 2019 | Others | ₹1.00 M | Open |
How Many Employees Work at I-Oxin Pharma?
Unlock and access historical data on people associated with I-Oxin Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of I-Oxin Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped I-Oxin Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
